-+ 0.00%
-+ 0.00%
-+ 0.00%
CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.
Share
Listen to the news
CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending